Press releases

• May 10, 2022 - Regulatory press releaseEisai completes rolling submission to the FDA of lecanemab for early Alzheimer’s disease under the accelerated approval pathway
• May 6, 2022 - Other press releaseBioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson’s disease
• May 5, 2022 - Regulatory press releaseReport from annual general meeting in BioArctic AB (publ)

Archive

Calendar

• July 12, 2022Interim report January – June 2022
• October 20, 2022Interim report January – September 2022
• February 3, 2023Full Year Report January – December 2022

Read more

Interim report Q1 2022

BioArctic AB published the company’s First Quarter Report for January – March 2022 on Thursday, April 28, 2022, at 08:00 a.m. CET.

• Report
• Presentation
• Webcast

Read the report

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more